There’s Still Time to Buy Pfizer Inc. (NYSE:PFE) Stock

In yesterday’s Wall Street session, Pfizer Inc. (NYSE:PFE) shares traded at $28.98, down -1.70% from the previous session.

26 analysts cover Pfizer Inc. (NYSE:PFE), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $75.00 and a low of $32.00, we find $36.50. Given the previous closing price of $29.48, this indicates a potential upside of 23.81 percent. PFE stock price is now -10.81% away from the 50-day moving average and -22.39% away from the 200-day moving average. The market capitalization of the company currently stands at $163.63B.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


The stock has received a hold rating from 14 analysts and a buy rating from 11. Brokers who have rated the stock have averaged $39.71 as their price target over the next twelve months.

In other news, Gottlieb Scott, Director bought 1,000 shares of the company’s stock on May 08. The stock was bought for $38,580 at an average price of $38.58. Upon completion of the transaction, the Director now directly owns 6,000 shares in the company, valued at $0.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 05, Director Gottlieb Scott bought 1,000 shares of the business’s stock. A total of $38,425 was incurred on buying the stock at an average price of $38.42. This leaves the insider owning 5,000 shares of the company worth $0.14 million. Insiders disposed of 545,539 shares of company stock worth roughly $15.81 million over the past 1 year. A total of 0.04% of the company’s stock is owned by insiders.

During the past 12 months, Pfizer Inc. has had a low of $29.02 and a high of $54.93. As of last week, the company has a debt-to-equity ratio of 0.66, a current ratio of 2.38, and a quick ratio of 2.05. The fifty day moving average price for PFE is $32.49 and a two-hundred day moving average price translates $37.34 for the stock.

The latest earnings results from Pfizer Inc. (NYSE: PFE) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at -$0.17, beating analysts’ expectations of -$0.34 by 0.17. This compares to $1.51 EPS in the same period last year. The net profit margin was 15.27% and return on equity was 11.05% for PFE. The company reported revenue of $13.23 billion for the quarter, compared to $22.64 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -41.55 percent. For the current quarter, analysts expect PFE to generate $14.33B in revenue.

Pfizer Inc.(PFE) Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Related Posts